Andrea Alimonti honored with distinguished 2024 Cloëtta Prize
Institutional Communication Service
Professor Andrea Alimonti, Group Leader at the Institute of Oncology Research (IOR, affiliated to USI and member of Bios+), will receive the 2024 Cloëtta Prize. This prestigious accolade represents a significant recognition of Professor Alimonti's exceptional contributions to the field of cancer research.
The Prof. Dr. Max Cloëtta Foundation aims at supporting and promoting medical research as well as related disciplines of natural sciences in Switzerland. The Foundation annually awards a Prize to support Swiss and foreign scientists who have made exceptional contributions to specific areas of medical research. It is one of the most prestigious awards given in Switzerland.
Andrea Alimonti is being honoured for his outstanding achievements in his studies on cellular senescence and tumour immunology that have led to the identification of new therapies for metastatic prostate cancer.
The major scientific contributions of Professor Alimonti's research include the discovery of a therapeutic approach based on the induction of cellular senescence and the immune response against tumors; the identification of an immune cell type, the so-called myeloid-derived suppressor cells, which can promote the progression of prostate cancer and resistance to standard therapies. Professor Alimonti's vision is to develop cutting-edge, innovative treatments for cancer patients. Some of these treatments are currently being tested in clinical trials.
The award ceremony, during which Prof. Alimonti will be introduced by Prof. Franco Cavalli, will take place on Friday, November 29, 2024, at 5 pm, at ETH in Lausanne.
